

## SynAct strengthens its patent portfolio

**SynAct Pharma AB (publ) ("SynAct") today announced that its recently acquired affiliate, TXP Pharma AG ("TXP"), was granted a patent in Canada related to "Alpha- and gamma-MSH analogues". In addition, TXP's patent application in another patent family relating to "Exendin-4-analogues" has entered national phase in significant countries and regions worldwide.**

TXP Pharma operates as a fully owned subsidiary and was recently acquired to strengthen SynAct Pharma's position in autoimmune diseases.

Alpha- and gamma-MSH analogues are peptides based on modifications of endogenous ligands to the melanocortin receptors, that plays a pivotal role in resolution of inflammation. TXP has applied its Branched Amino Acid Probes (BAP) to these peptides, and the new patent in Canada belongs to a family, where patents have been issued in several countries and regions, including Europe, Japan, and USA.

The Exendin-4-analogues are currently not a strategic focus point for SynAct Pharma, but it demonstrates the versatility of the BAP-technology that is a key asset in TXP Pharma. The BAP-modification of peptides has a large potential in a variety of indications and for the development of novel drugs, including the melanocortin analogue TXP-11, the leading peptide drug candidate, and other melanocortin analogues developed by TXP Pharma.

The patent application will be evaluated by the individual authorities in a process that may vary from country to country, and will, if successful, result in granting of patents as a next step.

*The information was submitted, through the agency of the contact person below, for publication at 07:00 a.m CEST on March 23, 2023*

**For further information, please contact:**

Jeppé Øvlesen, CEO

Phone: +45 28 44 75 67

Mail: [joo@synactpharma.com](mailto:joo@synactpharma.com)

Thomas Jonassen, CSO

Phone: +45 40 15 66 69

Mail: [tj@synactpharma.com](mailto:tj@synactpharma.com)

**About SynAct Pharma AB**

SynAct Pharma AB (publ) (Nasdaq Stockholm: SYNACT) conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms. For more information: [www.synactpharma.com](http://www.synactpharma.com).

**Attachments**

[SynAct strengthens its patent portfolio](#)